• Something wrong with this record ?

NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma

Z. Strizova, P. Taborska, D. Stakheev, S. Partlová, K. Havlova, S. Vesely, J. Bartunkova, D. Smrz,

. 2019 ; 37 (7) : 503-509. [pub] 20190426

Language English Country United States

Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025815

Grant support
NV16-28135A MZ0 CEP Register

OBJECTIVES: Renal cell carcinoma (RCC) is the most lethal urologic malignancy with increasing incidence worldwide. The conventional treatment strategies for advanced or recurrent RCC are not efficient and show considerable toxicities. Adoptive cell transfer (ACT) has become a promising treatment option for multiple cancers, particularly in combination with other therapeutic approaches. ACT often utilizes extensively in vitro expanded tumor-infiltrating lymphocytes (TILs). However, TILs are a very heterogeneous mix of cell populations and only those populations that have a cytotoxic and migratory potential are thought to deliver a therapeutic impact in ACT. The identification and localization of these therapeutically potent populations are therefore needed. METHODS AND MATERIALS: A total number of 57 tissue samples from 19 RCC patients who underwent radical nephrectomy was analyzed. The tissue samples were obtained from the tumor, peritumoral tissue, and the adjacent healthy renal tissue. The tissues were sliced, enzymatically dissociated into single cell suspensions and the obtained cells further analyzed by flow cytometry for the expression of markers of lymphocyte cytotoxicity - TRAIL and FasL, and a surrogate marker of lymphocyte migratory activity - PECAM-1. The analyzed data were next correlated with the clinical and histopathological data. RESULTS: Non-clear cell RCC (non-ccRCC) tumors showed a significantly decreased tumor infiltration with TRAIL+FasL+ NK cells but elevated infiltration with FasL+PECAM-1+ T cells as compared with clear cell RCC (ccRCC) tumors. Further analyses revealed that the peritumoral tissue of ccRCC patients is a reservoir of TRAIL+FasL+, TRAIL+PECAM-1+, or FasL+PECAM-1+ NK and T cells. CONCLUSIONS: The cytotoxic/migratory lymphocytes were identified in tumors of ccRCC patients. These lymphocytes became excluded from the tumor and accumulated in the patient's peritumoral tissue.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025815
003      
CZ-PrNML
005      
20201222155446.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.urolonc.2019.03.014 $2 doi
035    __
$a (PubMed)31030972
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Strizova, Zuzana $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
245    10
$a NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma / $c Z. Strizova, P. Taborska, D. Stakheev, S. Partlová, K. Havlova, S. Vesely, J. Bartunkova, D. Smrz,
520    9_
$a OBJECTIVES: Renal cell carcinoma (RCC) is the most lethal urologic malignancy with increasing incidence worldwide. The conventional treatment strategies for advanced or recurrent RCC are not efficient and show considerable toxicities. Adoptive cell transfer (ACT) has become a promising treatment option for multiple cancers, particularly in combination with other therapeutic approaches. ACT often utilizes extensively in vitro expanded tumor-infiltrating lymphocytes (TILs). However, TILs are a very heterogeneous mix of cell populations and only those populations that have a cytotoxic and migratory potential are thought to deliver a therapeutic impact in ACT. The identification and localization of these therapeutically potent populations are therefore needed. METHODS AND MATERIALS: A total number of 57 tissue samples from 19 RCC patients who underwent radical nephrectomy was analyzed. The tissue samples were obtained from the tumor, peritumoral tissue, and the adjacent healthy renal tissue. The tissues were sliced, enzymatically dissociated into single cell suspensions and the obtained cells further analyzed by flow cytometry for the expression of markers of lymphocyte cytotoxicity - TRAIL and FasL, and a surrogate marker of lymphocyte migratory activity - PECAM-1. The analyzed data were next correlated with the clinical and histopathological data. RESULTS: Non-clear cell RCC (non-ccRCC) tumors showed a significantly decreased tumor infiltration with TRAIL+FasL+ NK cells but elevated infiltration with FasL+PECAM-1+ T cells as compared with clear cell RCC (ccRCC) tumors. Further analyses revealed that the peritumoral tissue of ccRCC patients is a reservoir of TRAIL+FasL+, TRAIL+PECAM-1+, or FasL+PECAM-1+ NK and T cells. CONCLUSIONS: The cytotoxic/migratory lymphocytes were identified in tumors of ccRCC patients. These lymphocytes became excluded from the tumor and accumulated in the patient's peritumoral tissue.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a karcinom z renálních buněk $x imunologie $x patologie $x chirurgie $7 D002292
650    _2
$a separace buněk $7 D002469
650    _2
$a cytotoxicita imunologická $7 D003602
650    _2
$a ligand Fas $x metabolismus $7 D053222
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x cytologie $x imunologie $x patologie $x chirurgie $7 D007668
650    _2
$a nádory ledvin $x imunologie $x patologie $x chirurgie $7 D007680
650    _2
$a buňky NK $x imunologie $x metabolismus $7 D007694
650    _2
$a tumor infiltrující lymfocyty $x imunologie $x metabolismus $7 D016246
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nefrektomie $7 D009392
650    _2
$a antigeny CD31 $x metabolismus $7 D019408
650    _2
$a T-lymfocyty $x imunologie $x metabolismus $7 D013601
650    _2
$a protein TRAIL $x metabolismus $7 D053221
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Taborska, Pavla $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
700    1_
$a Stakheev, Dmitry $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
700    1_
$a Partlová, Simona $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
700    1_
$a Havlova, Klara $u Department of Urology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
700    1_
$a Vesely, Stepan $u Department of Urology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
700    1_
$a Bartunkova, Jirina $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic.
700    1_
$a Smrz, Daniel $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic. Electronic address: daniel.smrz@lfmotol.cuni.cz.
773    0_
$w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 37, č. 7 (2019), s. 503-509
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31030972 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155442 $b ABA008
999    __
$a ok $b bmc $g 1599960 $s 1116501
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 37 $c 7 $d 503-509 $e 20190426 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
GRA    __
$a NV16-28135A $p MZ0
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options